Advances in Targeting IKK and IKK-Related Kinases for Cancer Therapy

IκB kinases (IKK) and IKK-related kinases play critical roles in regulating the immune response through nuclear factor-κB and IFN regulatory factor–dependent signaling transduction cascades. Recently, these kinases have been implicated in the pathogenesis of many human diseases, including cancer. In fact, dysregulation of IKK activities promotes tumor survival, proliferation, migration, metastasis, and angiogenesis—common characteristics of many types of human cancers. Because of their oncogenic effects in human cancer development, targeting IKK and IKK-related kinases is becoming an increasingly popular avenue for the development of novel therapeutic interventions for cancer. This review will briefly cover the recent discovery of the downstream substrates of IKK and IKK-related kinases, and outline the strategies used for targeting IKK as a therapeutic intervention for cancer.

[1]  M. Karin,et al.  Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2009, Nature.

[2]  M. Hung,et al.  All Roads Lead to mTOR: Integrating Inflammation and Tumor Angiogenesis , 2007, Cell cycle.

[3]  G. Hortobagyi,et al.  IKKβ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway , 2007, Cell.

[4]  S. Akira,et al.  The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis , 2007, The Journal of experimental medicine.

[5]  Eric S. Lander,et al.  Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene , 2007, Cell.

[6]  M. Hung,et al.  Phosphorylation of CBP by IKKα Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NF-κB , 2007 .

[7]  David A. Cheresh,et al.  Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2007, Nature.

[8]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-κB and IKK function , 2007, Nature Reviews Molecular Cell Biology.

[9]  Cun-Yu Wang,et al.  IKKα stabilizes cytosolic β-catenin by inhibiting both canonical and non-canonical degradation pathways , 2006 .

[10]  A. Baldwin,et al.  Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression , 2006, Oncogene.

[11]  Michael Karin,et al.  Regulation and Function of IKK and IKK-Related Kinases , 2006, Science's STKE.

[12]  M. White,et al.  RalB GTPase-Mediated Activation of the IκB Family Kinase TBK1 Couples Innate Immune Signaling to Tumor Cell Survival , 2006, Cell.

[13]  M. Hepperle,et al.  A Selective Small Molecule IκB Kinase β Inhibitor Blocks Nuclear Factor κB-Mediated Inflammatory Responses in Human Fibroblast-Like Synoviocytes, Chondrocytes, and Mast Cells , 2006, Journal of Pharmacology and Experimental Therapeutics.

[14]  Ira Pastan,et al.  Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Rui Li,et al.  IκB Kinase α Regulates Subcellular Distribution and Turnover of Cyclin D1 by Phosphorylation* , 2005, Journal of Biological Chemistry.

[16]  Michael Karin,et al.  IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy , 2005 .

[17]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[18]  A. Ullrich,et al.  Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. , 2005, Cancer research.

[19]  G. Firestein,et al.  Regulation of c-Jun Phosphorylation by the IκB Kinase-ε Complex in Fibroblast-Like Synoviocytes1 , 2005, The Journal of Immunology.

[20]  Shao-Cong Sun,et al.  Regulation of the Deubiquitinating Enzyme CYLD by IκB Kinase Gamma-Dependent Phosphorylation , 2005, Molecular and Cellular Biology.

[21]  R. Gaynor,et al.  Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. , 2005, Molecular cell.

[22]  E. Kieff,et al.  IκB kinase β phosphorylates Dok1 serines in response to TNF, IL-1, or γ radiation , 2004 .

[23]  M. Madsen,et al.  Anticancer agent CHS 828 suppresses nuclear factor‐κB activity in cancer cells through downregulation of IKK activity , 2004, International journal of cancer.

[24]  Shao-Cong Sun,et al.  IκB Kinase Is an Essential Component of the Tpl2 Signaling Pathway , 2004, Molecular and Cellular Biology.

[25]  Osamu Takeuchi,et al.  The Roles of Two IκB Kinase-related Kinases in Lipopolysaccharide and Double Stranded RNA Signaling and Viral Infection , 2004, The Journal of experimental medicine.

[26]  M. Schmitz,et al.  Transient and Selective NF-κB p65 Serine 536 Phosphorylation Induced by T Cell Costimulation Is Mediated by IκB Kinase β and Controls the Kinetics of p65 Nuclear Import 1 , 2004, The Journal of Immunology.

[27]  Ryuji Kobayashi,et al.  IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a , 2004, Cell.

[28]  T. Maniatis,et al.  IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  K. McIntyre,et al.  A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. , 2003, Arthritis and rheumatism.

[30]  J. Adams,et al.  Novel IKK inhibitors: β-carbolines , 2003 .

[31]  M. Yao,et al.  A Selective IKK-2 Inhibitor Blocks NF-κB-dependent Gene Expression in Interleukin-1β-stimulated Synovial Fibroblasts* , 2003, Journal of Biological Chemistry.

[32]  Brian D. Strahl,et al.  A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression , 2003, Nature.

[33]  R. Gaynor,et al.  Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression , 2003, Nature.

[34]  T. Maniatis,et al.  IKKε and TBK1 are essential components of the IRF3 signaling pathway , 2003, Nature Immunology.

[35]  Shao-Cong Sun,et al.  NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase. , 2003, Molecular cell.

[36]  R. Surabhi,et al.  TAK1 is Critical for IκB Kinase-mediated Activation of the NF-κB Pathway , 2003 .

[37]  R. Gaynor,et al.  IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. , 2003, Molecular biology of the cell.

[38]  James R. Burke,et al.  BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice* , 2003, The Journal of Biological Chemistry.

[39]  M. Goldman,et al.  Structure–Activity Relationship Studies of Ethyl 2-[(3-Methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: An Inhibitor of AP-1 and NF-κB Mediated Gene Expression , 2002 .

[40]  M. Hung,et al.  A multicenter phase II study of tgDCC‐E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma , 2002, Head & neck.

[41]  J. Qin,et al.  Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator Activity by IκB Kinase , 2002, Molecular and Cellular Biology.

[42]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[43]  R. Gaynor,et al.  Regulation of β-Catenin Function by the IκB Kinases* , 2001, The Journal of Biological Chemistry.

[44]  K. Makino,et al.  E1A inhibition of radiation-induced NF-κB activity through suppression of IKK activity and IκB degradation, independent of Akt activation , 2001 .

[45]  M. Kasuga,et al.  Inhibition of the Motility and Growth of B16F10 Mouse Melanoma Cells by Dominant Negative Mutants of Dok-1 , 2001, Molecular and Cellular Biology.

[46]  P. Pandolfi,et al.  Phosphoinositide 3-Kinase–Dependent Membrane Recruitment of P62dok Is Essential for Its Negative Effect on Mitogen-Activated Protein (Map) Kinase Activation , 2001, The Journal of experimental medicine.

[47]  P. Pandolfi,et al.  P62dok, a Negative Regulator of Ras and Mitogen-Activated Protein Kinase (Mapk) Activity, Opposes Leukemogenesis by P210bcr-abl , 2001, The Journal of experimental medicine.

[48]  G. Hortobagyi,et al.  Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  T. Reynolds,et al.  Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  P. Pandolfi,et al.  62 dok , a Negative Regulator of Ras and Mitogen-activated Protein Kinase ( MAPK ) Activity , Opposes Leukemogenesis by p 210 bcr-abl , 2001 .

[51]  T. Mak,et al.  Deficiency of T2K leads to apoptotic liver degeneration and impaired NF‐κB‐dependent gene transcription , 2000, The EMBO journal.

[52]  S. Ghosh,et al.  Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex , 2000 .

[53]  Cherrington,et al.  SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. , 2000, Cancer research.

[54]  A. Ashworth,et al.  Identification of the familial cylindromatosis tumour-suppressor gene , 2000, Nature Genetics.

[55]  M. Karin,et al.  NAK is an IκB kinase-activating kinase , 2000, Nature.

[56]  M. Hung,et al.  β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression , 2000 .

[57]  E. Appella,et al.  p53 Regulates the Expression of the Tumor Suppressor Gene Maspin* , 2000, The Journal of Biological Chemistry.

[58]  Z. Estrov,et al.  E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  Z. Estrov,et al.  E 1 A-mediated Paclitaxel Sensitization in HER-2 / neu-overexpressing Ovarian Cancer SKOV 3 . ip 1 through Apoptosis Involving the Caspase-3 Pathway 1 , 2000 .

[60]  T. Skov,et al.  CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. , 1999, Cancer research.

[61]  S. Akira,et al.  IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. , 1999, International immunology.

[62]  M. Hung,et al.  E1A Sensitizes Cells to Tumor Necrosis Factor-induced Apoptosis through Inhibition of IκB Kinases and Nuclear Factor κB Activities* , 1999, The Journal of Biological Chemistry.

[63]  S. Barber,et al.  Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages. Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation. , 1994, Journal of immunology.